The UK has launched a study to ascertain whether a third booster dose of Covid-19 vaccines can offer greater protection and immunity against the virus. The trial, called Cov-Boost, is expected to enrol 2,886 participants and will look into seven different Covid-19 vaccines as potential boosters, including those from AstraZeneca, Pfizer, Moderna, Novavax, Johnson & Johnson, Valneva, and CureVac. The third shots will be administered to people who have already received two doses of the Pfizer or AstraZeneca Covid-19 vaccine, with initial findings expected to be reported in September.
Clinical-stage therapeutics company Histogen and its partner Amerimmune have reported pan-caspase inhibitor emricasan’s potential in vitro benefit in acute and long-haul phases of Covid-19 in Allergy, the journal of the European Academy of Allergy and Clinical Immunology. The study found that when administered orally, emricasan can reduce caspase-related inflammation in tissues, thereby potentially helping in the treatment and prevention of downstream Covid-19-related complications. The drug is currently being studied in a Phase I trial in mild-symptomatic Covid-19 patients at SUNY Downstate Medical Center in New York, with the study expected to complete in the second quarter of 2021.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Mumbai-headquartered drugmaker BDR Pharma has signed a non-exclusive licensing agreement with Eli Lilly to manufacture and distribute baricitinib, a repurposed drug for treating Covid-19. The partnership is intended to increase the availability of the drug in India. BDR has also submitted a request to the Drugs Controller General of India for restricted emergency use of the drug for Covid-19.
